



Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control

Pierre-Simon Bellaye^{1,2}, Guillaume Beltramo^{1,2,3}, Olivier Burgy^{2,3}, Bertrand Collin^{1,4}, Alexandre Cochet^{1,5} and Philippe Bonniaud^{2,3}

¹Centre George-François Leclerc, Service de médecine nucléaire, Plateforme d'imagerie et de radiothérapie précliniques, Dijon, France. ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, Dijon, France. ³INSERM U1231, Equipe HSP-pathies, Dijon, France. ⁴Institut de Chimie Moléculaire de l'Université de Bourgogne, UMR CNRS 6302, Université de Bourgogne Franche-Comté, Dijon, France. ⁵ImVIA, EA 7535, Université de Bourgogne, Dijon, France.

Corresponding author: Pierre-Simon Bellaye (psbellaye@cgfl.fr)



Shareable abstract (@ERSpublications)

Despite the discouraging results provided by Porter and co-workers, we believe that there is room for improvements, mainly by using better controls, which may ultimately lead to more promising outcomes for the use of hypoxia-focused imaging in IPF patients <https://bit.ly/30Ku2AV>

Cite this article as: Bellaye P-S, Beltramo G, Burgy O, *et al.* Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control. *Eur Respir J* 2022; 59: 2102711 [DOI: 10.1183/13993003.02711-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 13 Oct 2021
Accepted: 18 Nov 2021

To the Editor:

We read with great interest the paper by PORTER *et al.* [1] published in the October 2021 issue of the *European Respiratory Journal*. The authors' aim was to explore the potential benefit of the hypoxia tracer [¹⁸F]fluoromisonidazole ([¹⁸F]F-MISO) in idiopathic pulmonary fibrosis (IPF). Given the lack of non-invasive imaging tools for the diagnosis and/or the follow-up of patients with IPF, this study appears to be an essential first step towards the personalised management of IPF patients through imaging biomarkers for early/active fibrosis. *In vivo* molecular imaging, in particular positron emission tomography (PET), has become a crucial tool in preclinical research, clinical trials and medical practice, especially in the field of oncology. In lung fibrosis, recent advances have been made with the aim of developing molecular imaging tools in preclinical models, a necessary step toward clinical certification [2]. Among tracers validated at the preclinical level, imaging probes targeting collagen (⁶⁸Ga-CBP8 [3]), integrins ([¹⁸F]FB-A20FMDV2 [4]) and glucose metabolism ([¹⁸F]FDG [5]) have been successfully evaluated in clinical trials and may ultimately improve IPF management.

